
    
      OBJECTIVES: I. Determine whether donor hematopoiesis can be safely established using a
      nonmyeloablative conditioning regimen followed by HLA matched sibling donor peripheral blood
      stem cell transplantation in patients with hematologic malignancies. II. Determine whether
      mixed chimerism can be safely converted to full donor hematopoiesis with this treatment
      regimen in these patients. III. Determine the toxicity and incidence of aplasia and graft
      versus host disease in these patients treated with this regimen. IV. Determine the antitumor
      potential of this treatment regimen in these patients. V. Determine the role of NFkB in the
      modulation of the cytokine secretion profile of T lymphocytes during an alloimmune response
      in these patients treated with this regimen.

      OUTLINE: Patients receive immunosuppressive medications consisting of oral mycophenolate
      mofetil and tacrolimus twice a day beginning on day -8 and continuing through day 45 (in the
      absence of graft versus host disease). Patients also receive daclizumab IV over 30 minutes on
      days -1, 3, and 8. Patients undergo allogeneic peripheral blood stem cell (PBSC)
      transplantation with donor CD34+ cells IV on day 0. If there is 0-80% donor hematopoiesis,
      patients receive donor lymphocyte infusions with CD3+ cells IV on days 75, 165, and 270.

      PROJECTED ACCRUAL: A total of 10-45 patients will be accrued for this study.
    
  